Lufenuron + Milbemycin Oxime + Praziquantel

Verify with FDA CVM →

2,444 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
2,444
Total Reports
26
Deaths Reported
110.0%
Death Rate

Active Ingredients

LufenuronMilbemycin OximePraziquantel

Administration Routes

OralUnknownOphthalmicRespiratory (Inhalation)

Species Affected

Dog 2,296
Unknown 146
Human 2

Most Affected Breeds

Retriever - Labrador 425
Unknown 148
Dog (unknown) 138
Retriever - Golden 126
Shepherd Dog - German 115
Crossbred Canine/dog 102
Pit Bull 83
Chihuahua 64
Beagle 63
Boxer (German Boxer) 57

Most Reported Reactions

INEFFECTIVE, HOOKS 528
Lack of efficacy (endoparasite) - heartworm 422
Vomiting 382
Lack of efficacy (heartworm) 199
Diarrhoea 176
Lethargy (see also Central nervous system depression in 'Neurological') 141
INEFFECTIVE, HEARTWORM LARVAE 137
Lack of efficacy (roundworm) 127
Product problem 123
Containers, Damaged 86
Lack of efficacy (endoparasite) - roundworm NOS 79
Underdose 72

Outcome Breakdown

Outcome Unknown
1,659 (72.2%)
Recovered/Normal
578 (25.1%)
Ongoing
33 (1.4%)
Euthanized
13 (0.6%)
Died
13 (0.6%)
Recovered with Sequela
3 (0.1%)

Data Summary

Metric Value
Total adverse event reports 2,444
Reports involving death 26
Case-fatality rate (reported events) 110.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Lufenuron + Milbemycin Oxime + Praziquantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 2,444 adverse event reports referencing Lufenuron + Milbemycin Oxime + Praziquantel, including 26 reports in which the animal died — a 110.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Lufenuron, Milbemycin Oxime, Praziquantel. Reported administration routes include Oral, Unknown, Ophthalmic, Respiratory (Inhalation). These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Lufenuron + Milbemycin Oxime + Praziquantel reports are Dog (2,296 reports), Unknown (146 reports), Human (2 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (425), Unknown (148), Dog (unknown) (138) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Lufenuron + Milbemycin Oxime + Praziquantel are INEFFECTIVE, HOOKS (528), Lack of efficacy (endoparasite) - heartworm (422), Vomiting (382), Lack of efficacy (heartworm) (199). Of the 2,299 reports with a coded outcome, Outcome Unknown is the leading category at 72.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Lufenuron + Milbemycin Oxime + Praziquantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial